Abeona Therapeutics Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.51. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | VNQI | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $50.76 |
52-Week Low | $4.17 | $43.26 |
Enterprise Value | $276.10M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.72, up 0.35% with a bullish technical signal from moving averages. The ETF provides diversified international real estate exposure across 30+ countries outside the U.S. with a competitive expense ratio and higher dividend yield compared to domestic REIT ETFs. Recent institutional activity shows Balefire LLC reduced its position by 78.7% in Q2 2026.
The fund offers international real estate diversification benefits but faces currency risk and potential underperformance versus U.S. REITs. Current technical momentum supports near-term upside, though investors should weigh the trade-off between higher yield and historical total return lag against domestic alternatives.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →